0 CHECKOUT

Saving Graces: Why Net Capital Flows Are Pouring Out Of Rather Than Into East Asia May 08

  • ID: 1886886
  • May 2008
  • Region: Asia
  • Standard & Poors
1 of 3

FEATURED COMPANIES

  • Indonesia (Republic of)
  • Japan
  • Korea (Republic of)
  • Malaysia
  • Singapore (Republic of)
  • Thailand (Kingdom of)
  • MORE

Abstract
Economic logic is being turned on its head. Net capital flows should be pouring into East Asia (Indonesia, Malaysia, Thailand, Singapore, Vietnam, Cambodia, Philippines, China, Hong Kong, Taiwan, South Korea, and Japan), but are leaving it instead. While the region still benefits from foreign direct investments, it has recently become an increasingly important source of financing for governments and companies in advanced economies. And nowhere is this more evident than the U.S. Last year, East Asia's net purchases of U.S. portfolio assets amounted to 32.5% the U.S.'s current account deficit. Yet, with the exception of Japan and Singapore, average income in East Asia remains far below U.S. levels (see chart 1). In theory, investments in East Asian economies should yield...

Companies mentioned in this report are:
- Japan
- Hong Kong (Special Administrative Region)
- Malaysia
- Thailand (Kingdom of)
- Korea (Republic of)
- Singapore (Republic of)
- Taiwan (Republic of China)
- China (People's Republic of )
- Indonesia (Republic of)
- Philippines (Republic of the)
- Vietnam (Socialist Republic of)

Standard and Poors RatingsXpress READ MORE >

Note: Product cover images may vary from those shown
2 of 3

- Japan
- Hong Kong (Special Administrative Region)
- Malaysia
- Thailand (Kingdom of)
- Korea (Republic of)
- Singapore (Republic of)
- Taiwan (Republic of China)
- China (People's Republic of )
- Indonesia (Republic of)
- Philippines (Republic of the)
- Vietnam (Socialist Republic of)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.